Skip to search formSkip to main contentSkip to account menu
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
View on PubMed
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
TLDR
Tamoxifen citrate, which inhibits the action of estrogen on breast tissue, improves disease-free survival among women who have estrogen receptor, and raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue and estrogenIC effects on bone, lipid metabolism, and blood clotting.
View via Publisher
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
View on Elsevier
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.
TLDR
Three continuous lines of mammary tumor cells have been established from malignant effusions of two women with breast cancer, and two of the cultures, although derived from the same patient, have stable differences in their karyotypes.
View on PubMed
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines
TLDR
Data from these cell lines suggest that human breast cancer progression results first in the loss of ER, and subsequently in VIM acquisition, the latter being associated with increased metastatic potential through enhanced invasiveness.
View on Wiley
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.
TLDR
In the management of stage I and II breast cancer, breast conservation with lumpectomy and radiation offers results at 10 years that are equivalent to those with mastectomy.
View on PubMed
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
TLDR
It is concluded that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after 4 years of treatment, through prevention of new cancers or suppression of subclinical tumors, or both.
View on Springer
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.
TLDR
Analysis of expression microarrays makes it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes.
View on PubMed
Tamoxifen for early breast cancer: an overview of the randomised trials
View on Elsevier
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
TLDR
The data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License